Abstract: Rain streaks in outdoor images can severely affect the performance of high-level vision tasks, such as surveillance and autonomous driving, by obscuring important image details. The ...

Abstract: Nowadays, as the demand for accurate object detection (OD) applications is increasing, several attempts have been made to introduce convolutional neural network (CNN)-based super-resolution ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

SALT LAKE CITY - Recursion (NASDAQ:RXRX) will present new clinical data from its ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP) during a company webinar scheduled ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...